Novos response to the growing competition is the planned launch this month of a more affordable authorised copy of Ozempic in South Africa, through a partnership with healthcare company Acino aimed at expanding patient access
Rubino DM, Greenway FL, Khalid U, ONeil PM, Rosenstock J, Srrig R, et al
A Decision Framework Lean toward Contrave if: Eating is primarily driven by cravings, reward-seeking, or emotional triggers You have depression that might benefit from bupropion You strongly prefer oral medication You cannot take GLP-1 medications Insurance covers Contrave but not semaglutide Weight loss goals are more modest (5-10%) Lean toward semaglutide if: You want maximum weight loss (15%+) You have cardiovascular disease or high risk You have diabetes or prediabetes Your eating is driven by persistent hunger and difficulty feeling full You prefer weekly over daily medication You can afford it or have coverage Either might work if: You have mixed eating patterns No clear medical factor driving choice Both are accessible and affordable Moderate weight loss would meet your goals Discuss With Your Provider Bring these considerations to your healthcare provider: Your specific eating patterns and challenges Your complete medical history and current medications Your weight loss goals Your insurance coverage and budget Your preferences about administration Your provider can help weigh these factors against your specific health profile
Patients whose diabetes is being managed with the support of semaglutide (sold as Ozempic) are likely to again encounter issues accessing the medication due to ongoing stock shortages
In addition to regulating lipolysis, semaglutide influences adipocyte lipid storage and turnover
Research-grade purity: Fit for educational and research use that demands high-quality peptides
.webp)
